UniProtKB/SwissProt variant VAR

Variant information

Variant position:

262

The position of the amino-acid change on the UniProtKB canonical protein sequence.

Type of variant:

LP/P [Disclaimer]

The variants are classified into three categories: LP/P, LB/B and US.

LP/P: likely pathogenic or pathogenic.
LB/B: likely benign or benign.
US: uncertain significance

Residue change:

From Serine (S) to Glycine (G) at position 262 (S262G, p.Ser262Gly).

Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.

Physico-chemical properties:

Change from small size and polar (S) to glycine (G)

The physico-chemical property of the reference and variant residues and the change implicated.

BLOSUM score:

0

The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:

Lowest score: -4 (low probability of substitution).
Highest score: 11 (high probability of substitution).

More information can be found on the following page

Variant description:

In SMA3.

Any additional useful information about the variant.

Other resources:

Links to websites of interest for the variant.

Variant rs104893932 [ dbSNP | Ensembl ]

Sequence information

Variant position:

262

The position of the amino-acid change on the UniProtKB canonical protein sequence.

Protein sequence length:

294

The length of the canonical sequence.

Location on the sequence:

IIPPPPPICPDSLDDADALG S MLISWYMSGYHTGYYMGFRQ

The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.

Residue conservation:

The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         IIPPPPPICPDSLDDADA----LGSMLISWYMSGYHTGYYMGFRQ

                              IIPPPPPICPDSLDDADA----LGSMLISWYMSGYHTGYYM

Mouse                         IIPPPPPISPDCLDDTDA----LGSMLISWYMSGYHTGYYM

Rat                           IIPPPPPISPDCLDDTDA----LGSMLISWYMSGYHTGYYM

Bovine                        MIPPPPPICPDSLDDADA----LGSMLISWYMSGYHTGYYM

Cat                           IIPPPPPICPDSLDDADA----LGSMLISWYMSGYHTGYYM

Drosophila                    VMPPMPPVPPMIVGQGDGAEQDFVAMLTAWYMSGYYTGLYQ

Fission yeast                 FMEVPPPIRGLTYDET------YKKLIMSWYYAGYYTGLAE

Sequence annotation in neighborhood:

The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:

Type: the type of sequence feature.
Positions: endpoints of the sequence feature.
Description: contains additional information about the feature.

Type	Positions	Description
Chain	2 – 294	Survival motor neuron protein
Region	240 – 267	P2 (binding site for SNRPB)
Region	252 – 280	Involved in homooligomerization
Mutagenesis	260 – 260	L -> S. Impairs homooligomerization.
Mutagenesis	263 – 263	M -> RTA. Impairs homooligomerization and GEMIN8 binding.
Mutagenesis	264 – 264	L -> A. Impairs homooligomerization.
Mutagenesis	266 – 266	S -> P. Impairs homooligomerization and GEMIN8 binding.
Mutagenesis	267 – 267	W -> A. Impairs homooligomerization.
Mutagenesis	268 – 268	Y -> A. Impairs homooligomerization.
Mutagenesis	271 – 271	G -> A. Impairs homooligomerization.
Mutagenesis	272 – 272	Y -> A. Impairs homooligomerization.
Mutagenesis	273 – 273	H -> R. Impairs GEMIN8 binding.
Mutagenesis	274 – 274	T -> A. Impairs homooligomerization.
Mutagenesis	275 – 275	G -> A. Impairs homooligomerization.
Mutagenesis	279 – 279	G -> E. Impairs homooligomerization.

Literature citations

Molecular and functional analysis of intragenic SMN1 mutations in patients with spinal muscular atrophy.
Sun Y.; Grimmler M.; Schwarzer V.; Schoenen F.; Fischer U.; Wirth B.;
Hum. Mutat. 25:64-71(2005)
Cited for: VARIANTS SMA1/SMA2/SMA3 ASN-30; VAL-44; ARG-95; GLY-111; GLY-262; CYS-272 AND ILE-274; CHARACTERIZATION OF VARIANTS SMA1/SMA2/SMA3 ASN-30; VAL-44; ARG-95 AND GLY-111;

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot Q16637: Variant p.Ser262Gly